Having extended the booster shot approvals to Moderna and Johnson&Johnson, the United States Food and Drug Administration announced on Wednesday that they will be authorizing the mixing of different COVID-19 booster shots, allowing for optimal combinations to be administered to those in need.

Peter Marks, FDA’s Biology Evaluation and Research director, stated that the move to authorize emergency use doses is based on currently available data and input from the members of the advisory committee.

The FDA reassured the general public that they are doing their best to gather substantial amounts of information as quickly as possible.

With that info, the pros and cons of mixing and matching separate jabs will be far more apparent.

This plan is set to roll out in the following weeks.

New regulations on booster shots

As it stands, eligibility for the Moderna shot is exclusive to those 65 and older, those aged 18-64 with past medical records that put them at risk of a severe case of COVID-19, and anyone in that same age group whose occupation forces them to have constant exposure to the virus.

The FDA recommends that those who completed their first round of vaccination wait at least 6 months before opting for the Moderna shot.

Johnson&Johnson’s eligibility is set to those 18 and older, and those who completed their first complete vaccination should wait at least 2 months before being jabbed.

So far, the only vaccine with full approval from the agency is Pfizer’s, having been authorized last month as a booster dose.

Despite the advisory panel’s original voting score of 16-3 in favor of NOT authorizing boosters for all healthy Americans, arguing that only those in dire need of one should qualify, the regulator has steadily expanded booster jab usage to most age groups, regardless of occupation or medical history.

Formerly, US president Sleepy Joe Biden had already stated that the universal booster shots are ready to roll out, although, maybe a bit too early due to the FDA’s hesitance to debate on the matter.

Mixing vaccine shots isn’t a new practice and researchers in the UK have begun new studies on combining immunizations.

These will mainly focus on the younger demographic, aged 12-15, taking into account the effects of Pfizer, Moderna, and Novavax jabs.